From molecular language to practical research literacy
Built from five Peptides in Practice volumes — fundamentals, A–Z profiles, protocols, history, reconstitution, safety and ethics. 27 research peptides. Seven biological territories. One framework for reading the science without the hype.
A visual map of the Nexus. Every section builds toward one skill: reading peptide science without selling yourself on the signal.
Your body speaks a language. Peptides are part of the conversation — not the whole story.
Peptides are short chains of amino acids that bind receptors and influence specific biological pathways. The emphasis is on signaling rather than brute-force stimulation. The real question: what signal does it change, where, and what happens next?
The lock-and-key concept runs throughout peptide biology. A peptide can change a pathway because a receptor recognizes its structure. That specificity is also why route, dose, and timing matter — and why context determines outcome.
The biological terrain — inflammation, energy, sleep, metabolic health — comes before piling on additional signals. A peptide landing on a broken receiver produces a broken signal. Fix the terrain first.
The terrain comes before the stack. These three disruptions silence receptors and blunt every peptide signal above them.
27 peptides across seven biological territories. These are research domains and biological themes — not efficacy rankings or treatment recommendations.
Every peptide in the Nexus receives the same treatment: mechanism, evidence snapshot, research areas, known limitations, and the LevelUp takeaway. Read the signal before the hype.
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protective protein in human gastric juice. It has been extensively studied for regenerative, anti-inflammatory, and gastroprotective effects. Uniquely, it shows effectiveness in tissues with low blood supply — tendons, ligaments, gut lining — where healing is typically slowest.
| Research Focus | Gastroprotective protein fragment research |
| Category | Recovery / Tissue |
| Dose Range | 250–500 mcg/day |
| Route | Subcutaneous (near injury) or oral |
| Solvent | BAC Water |
| Stability | High (stable in acidic environment) |
TB-500 is placed in the regenerative category and linked to thymosin-beta-4 biology, cell migration and tissue repair. The important reading question is how much of that biology has translated into controlled human outcomes. Its mechanism — mobilizing progenitor cells and sending them to injury sites — is biologically compelling.
| Research Focus | Thymosin beta-4–related research |
| Category | Recovery / Tissue |
| Evidence Posture | Study-specific; verify current literature |
| Best Paired With | BPC-157 (complementary mechanisms) |
GHK-Cu is a naturally occurring copper-binding peptide associated with tissue remodeling, skin biology and extracellular-matrix signaling. The research story is broader than any single cosmetic or recovery claim — it touches collagen biology, wound healing, and anti-inflammatory pathways simultaneously.
CJC-1295 without DAC is a GHRH (growth hormone-releasing hormone) analog that stimulates the pituitary to produce physiological GH pulses — mimicking rather than replacing the body's natural secretory pattern. It is almost always used in combination with a GHRP like Ipamorelin to amplify the nocturnal GH peak without suppressing the HPG axis.
| Best Paired With | Ipamorelin (amplifies the GH peak) |
| Dose Range | 200–300 mcg |
| Timing | 30 min before sleep (nocturnal GH window) |
| Monitor | IGF-1 at baseline and week 8; reduce dose if >300 ng/mL |
Ipamorelin is a selective GHRP (growth hormone-releasing peptide) that amplifies GH secretion via the ghrelin receptor without significantly raising cortisol, prolactin, or ACTH — making it one of the cleanest secretagogues in the category. Its selectivity is its primary research advantage.
IGF-1 LR3 is a modified IGF-1 analog studied for prolonged IGF signaling. Because IGF pathways regulate growth and metabolism broadly, the mechanism carries both potential effects and meaningful safety considerations. The extended half-life — a key design feature — is also what requires careful monitoring.
Follistatin is a binding protein that can interact with members of the myostatin/activin family. The research question is whether modifying this signaling meaningfully changes muscle biology without cascading effects on other activin-dependent systems — fertility, bone, cardiovascular — that share the same pathway.
Tesamorelin is a GHRH analog with a defined clinical history for a specific indication: HIV-associated lipodystrophy. It is the most useful example in this guide for why regulatory status must be tied to the exact product, population, and indication — not generalized from one approval to all metabolic uses.
PEG-MGF is described as a longer-lasting form related to mechano-growth-factor biology. Research focuses on muscle-cell signaling and repair after mechanical stress. PEGylation extends the half-life of the native MGF splice variant of IGF-1 — the key design question is whether that extension translates to meaningful differences in outcome.
AOD-9604 is a modified fragment related to the 176–191 region of human growth hormone. The supplied material emphasizes adipose-tissue and lipolysis research rather than broad growth-hormone effects. This is an important distinction — the fragment is designed to retain the lipolytic activity of HGH while avoiding the growth-promoting or diabetogenic effects.
| Dose Range | 300–500 mcg (basic) → 500–800 mcg (advanced) |
| Timing | Morning fasted (basic/intermediate) |
| Solvent | Acetic Acid 0.6% (not BAC Water alone) |
MOTS-C is a mitochondrial-derived peptide studied for metabolic signaling and cellular stress responses. The source collection emphasizes AMPK-related biology and exercise/metabolic research. It represents an emerging class: peptides that originate from the mitochondrial genome — a relatively recent discovery in peptide biology.
Elamipretide (SS-31) is designed to interact with mitochondrial membranes and has been investigated in disorders involving mitochondrial dysfunction. It is a useful example of a compound that has progressed into human clinical trials for a serious indication — making it more than a theoretical mechanism.
Humanin is a mitochondrial-derived peptide investigated in cell-survival, metabolic and aging-related biology. Its appeal comes from a possible connection between mitochondrial signaling and resilience against cell death — particularly in neuronal and cardiac models.
Epitalon is a research peptide associated with pineal and telomere-related hypotheses. These mechanisms are scientifically interesting, but mechanistic plausibility is not the same as proven longevity benefit. Developed by the St. Petersburg Institute of Bioregulation, it has a longer research history than most compounds in this class.
5-Amino-1MQ is discussed as an NNMT inhibitor, with research interest in nicotinamide metabolism, NAD biology and metabolic function. The mechanism — inhibiting an enzyme that degrades NAD precursors — is more established than the clinical outcome claims that follow from it.
KPV is a short tripeptide fragment derived from alpha-MSH (α-melanocyte-stimulating hormone). It is studied for anti-inflammatory and epithelial-barrier effects — particularly in gut inflammation models. Most claims remain at the research stage, making it a promising but early-stage compound.
LL-37 is a naturally occurring human antimicrobial peptide involved in innate immunity. Research examines both antimicrobial activity and immune modulation, making its biology more complex than a simple "immune booster" description. It is the only member of the cathelicidin family in humans.
DSIP is an older experimental neuropeptide studied in relation to sleep and stress. The source material describes modulation of sleep-related centers; the strength of human evidence is the critical question. It remains one of the most practically-oriented neuro peptides for athletes with non-restorative sleep patterns.
Semax is a synthetic peptide studied primarily in Eastern European/Russian research traditions for neurological and cognitive effects. The key task is separating regional clinical use from the strength of the controlled evidence base — and understanding which claims rest on the strongest foundations.
Selank is an experimental neuropeptide studied in relation to stress, anxiety and neurochemical regulation. The research question is whether reported effects translate reliably across populations and study designs — particularly in contexts outside the Russian research tradition where most studies originate.
Semaglutide is a GLP-1 receptor agonist with established prescription uses in specific products and indications. Its biology illustrates how a peptide signal can move from receptor pharmacology into large-scale clinical trials and regulatory approval — the most advanced example in this entire guide of evidence translation done right.
Tirzepatide combines GIP and GLP-1 receptor activity. Its clinical development shows how multi-receptor signaling can produce measurable metabolic outcomes while also introducing class-specific tolerability considerations. Approved as Mounjaro for T2DM and as Zepbound for chronic weight management.
Retatrutide is an investigational multi-receptor agonist designed to engage GIP, GLP-1 and glucagon pathways. It is a strong example of why early clinical-trial results must remain separate from approval status — compelling phase 2 data is not a finished product.
Melanotan II is an experimental melanocortin agonist studied for pigmentation and other receptor-mediated effects. Its broad receptor activity — across MC1R through MC4R — is exactly why the compound should not be reduced to a simple tanning or libido agent. The breadth is the scientific story and the safety concern simultaneously.
Bremelanotide acts through melanocortin receptors in the central nervous system and has an FDA-approved indication for a specific female sexual-dysfunction population. The label matters: it defines the population studied, the dose, the indication, and the demonstrated safety profile — and it is specifically for premenopausal women with hypoactive sexual desire disorder (HSDD).
The source collection uses "HCG Frag 176-191" as an alternative name related to the 176–191 growth-hormone fragment — the same region as AOD-9604. This makes nomenclature and product identity especially important when evaluating claims. The naming confusion itself is a research-literacy issue worth addressing directly.
Klotho-related peptide concepts sit at the emerging edge of longevity and metabolic research. The science is better treated as a map of hypotheses than as a finished therapeutic category. Klotho as a protein has a fascinating biology — the gap is the translation to a practical peptide therapeutic.
The REC Method organizes biological systems into 7 axes with non-negotiable hierarchical order. Each axis has its clinical question and its specific peptides. Starting at the wrong level is the most common reason protocols fail.
| Axis | System | Key Question | Core Peptides |
|---|---|---|---|
1 | Inflammatory-Immune | How much inflammatory noise is there? | BPC-157, KPV, LL-37, Semax/Selank |
2 | Mitochondrial-Energetic | Is there cellular energy to sustain regeneration? | SS-31, MOTS-C, Humanin |
3 | Neurocentral | Is the CNS in noise mode or predictability? | Semax, Selank, DSIP, Epitalon |
4 | Metabolic-Incretinic | Does insulin work? Is there energy flexibility? | GLP-1, Tirzepatide, MOTS-C |
5 | Tissue-Structural | Is tissue repair happening? | BPC-157, TB-500, GHK-Cu |
6 | Epigenetic-Chronobiological | Is the circadian clock organized? | Epitalon, DSIP, GHK-Cu |
7 | Anabolic-Hormonal | Always last. Muscle mass, consolidation. | CJC-1295, Ipamorelin, IGF-1 LR3, Follistatin |
Developed from real clinical practice, the REC Method organizes peptide use into three non-negotiable phases. Without all three, the result is temporary.
Restore the biological terrain before anything else. Sleep, circadian rhythm, energy metabolism, neuroimmune communication, basic mitochondrial function. Peptides in this phase are modulators — support signals, never isolated protagonists. The terrain has to be ready to receive the signal.
Regenerating is not forcing growth. It is signaling the correct tissue at the correct moment. Bioactive peptides, neuropeptides, and mitochondrial peptides enter here — always in cycles, always with a pause, always with attention to the body's response. The pause is part of the protocol.
The greatest mistake is confusing improvement with sustainability. This phase reduces therapeutic dependence, increases biological autonomy, and teaches the organism to maintain its own optimized state. The goal is not perpetual peptide dependence — it is a body that can sustain what was achieved.
A degraded peptide looks identical to an active one. It doesn't change color, doesn't smell different, doesn't form visible precipitate. It simply doesn't work — and you won't know why. Prevention is the only real strategy.
| Lyophilized powder (regular use) | 2–8°C · Dark · Months–1-2 years |
| Lyophilized powder (long term) | −20°C · Dark · 3–5 years |
| Lyophilized powder (in use) | Room temp · Dark · Up to 2–4 weeks |
| Reconstituted with BAC Water | 2–8°C · Dark · 20–30 days |
| Reconstituted with Acetic Acid | 2–8°C · Dark · 45+ days |
| Reconstituted with CAG Water | 2–8°C · Dark · 30–40 days |
Formula: Desired dose (mcg) ÷ Concentration (mcg/mL) = Volume (mL) × 100 = Insulin syringe units
Responsible use requires knowing not only when to use peptides, but when to stop entirely. Biological activity is not the same thing as safety.
Ten rules for reading peptide science without selling yourself on the signal. Print them. Read them before every protocol decision.
The vocabulary that makes the science readable. Four domains: molecular language, signaling biology, research methodology, and safety/regulation.